Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Virginia Tysabri PML Injury Lawyer

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic options. Within this broad domain, the dissemination of balanced, evidence-based knowledge has empowered individuals to make informed decisions about their care. As the landscape of medical science evolves, so too does the need to address specific, real-world implications of treatment exposures. One such area of growing concern involves the intersection of advanced biologic therapies and the potential for serious adverse events that may require legal scrutiny. Transitioning from this general health context, attention now turns to the occupational and personal exposure risks associated with Tysabri, a medication used in the management of certain chronic conditions. Specifically, the link between Tysabri use and the development of Progressive Multifocal Leukoencephalopathy (PML) has emerged as a critical focus for patients and their families. For individuals in Virginia who have experienced such exposure and subsequent neurological injury, understanding the legal avenues for recourse becomes paramount. This shift from broad health education to targeted risk awareness underscores the necessity of specialized legal guidance for those affected by PML following Tysabri treatment, highlighting the need for experienced representation in navigating the complexities of pharmaceutical injury claims.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information contains a boxed warning stating that TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML is caused by the JC virus (JCV) and typically occurs only in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label identifies three factors that increase the risk of PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation and Diagnosis of PML

PML is a severe demyelinating disease that affects the brain. A large retrospective cohort study of 456 Italian PML patients observed between 1987 and 2024 described the demographic, clinical, radiological, and laboratory characteristics of the disease (https://pubmed.ncbi.nlm.nih.gov/40922664/). The study included cases with either a definite or clinico-radiological diagnosis (https://pubmed.ncbi.nlm.nih.gov/40922664/). The clinical presentation of PML can include progressive neurological deficits such as weakness, cognitive impairment, and coordination problems. Diagnosis typically relies on brain MRI findings and detection of JCV DNA in cerebrospinal fluid.

Mechanistic Pathway and Risk Factors

The mechanistic pathway linking Tysabri to PML involves the drug's mechanism of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in the brain but also impairs normal immune surveillance. In patients who carry JCV, the virus can reactivate and proliferate in the brain without adequate immune control, leading to PML. The risk is highest in patients who are anti-JCV antibody positive, have been on therapy for more than two years, or have previously used immunosuppressant medications (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adverse Event Reporting and Monitoring

The FDA Adverse Event Reporting System (FAERS) database lists adverse events most frequently associated with Tysabri, including fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, malaise, and drug ineffective (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly indicate PML, they reflect the range of neurological and systemic symptoms that patients may experience during treatment. The adequacy of warnings regarding Tysabri and PML is a critical issue. The boxed warning clearly states the increased risk and the need for monitoring. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations for Virginia Patients

Despite these measures, some patients may develop PML, and questions may arise about whether the warnings were sufficient or whether the risks were adequately communicated. For patients affected by PML after Tysabri use, attorney-related considerations may include evaluating whether the prescribing physician followed the recommended monitoring protocols and whether the patient was informed of the risk factors. The timeline between exposure to Tysabri and documented harm is important. PML can occur after months or years of treatment, with risk increasing after two years of therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Early symptoms may be subtle and progress rapidly, leading to severe disability or death. Patients who develop PML may require legal assistance to pursue claims related to inadequate warnings or failure to monitor. In summary, Tysabri carries a well-documented risk of PML, a serious brain infection. The drug's labeling includes a boxed warning and risk factors, but affected patients may still experience harm. Legal considerations for those in Virginia include assessing the adequacy of warnings and the timeline of exposure to harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a serious brain infection caused by the JC virus. The risk is higher in patients with anti-JCV antibodies, longer treatment duration (especially over two years), or prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML and how is it diagnosed?

PML symptoms include progressive weakness, cognitive impairment, and coordination problems. Diagnosis is based on brain MRI findings and detection of JCV DNA in cerebrospinal fluid (https://pubmed.ncbi.nlm.nih.gov/40922664/).

What legal options are available for Virginia patients who developed PML after Tysabri use?

Patients may pursue claims related to inadequate warnings or failure to monitor. An attorney can evaluate whether the prescribing physician followed recommended protocols and whether the patient was informed of risk factors. The timeline of exposure and harm is critical (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.